Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (November 2023)
32 slides from Health X Platform's investor presentation, Nov 14, 2023
Slide 1: Intimation under Regulation 30 – Investor Presentation
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 14-11-2023 To To Th
Slide 2: Investor Presentation November 2023
“Digital Platform of Pharma Supply Chain and Diagnostic providing access of quality healthcare for all” Investor Presentation November 2023
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: In this digital age, we have an opportunity to transform the lives of people
In this digital age, we have an opportunity to transform the lives of people in ways that were hard to imagine in the past. I see technology as a means of empowerment and as a tool that bridges the distance between hope and opportunity in this digital age. Shri Narendra Modi Hon’ble Prime Minister o
Slide 5: Leading Player in Indian Pharmaceutical & ePharmacy Distribution
Leading Player in Indian Pharmaceutical & ePharmacy Distribution B2C Platform • Strategic Partnership with Flipkart Pharmacy and Wellness Significant Play B2B Platform • eB2B platform distributing pharma and other in healthcare products to Pharmacies & other Pharmaceutical & other Retailers Healthca
Slide 6: Operating in High Growth Sectors – US$ 37 bn Addressable Market Growing at ~12%
Operating in High Growth Sectors – US$ 37 bn Addressable Market Growing at ~12% CAGR Indian Pharma Market ePharma Diagnostic (IPM) • Market size US$345 mn in • Market size US$24 bn 2 • Market size estimated US$ 13 2021 1 bn in 2023 3 • To grow at CAGR of 12% • To grow at CAGR of 14% • To grow at CAG
Slide 7: Q2 FY24 Key Financial Highlights – Healthcare Network
Q2 FY24 Key Financial Highlights – Healthcare Network Revenue ₹ cr ↑ 40% YOY Gross Margin ₹ cr ↑ 250 bps YOY EBITDA ₹ cr ↑ 430 bps YOY 40.0 10.6% 12.0% 6 2.0% 4.5 355.4 35.1 330.1 35.0 4 35.0 9.9% 311.5 10.0% 1.0% 2 1.4% 1.3 279.8 30.0 7.7% 0.4% 7.4% 7.6% 253.9 0 0.0% 8.0% 25.0 23.7 Q2FY23 Q3FY23 Q4
Slide 8: H1 FY24 Key Financial Highlights – Healthcare Network
H1 FY24 Key Financial Highlights – Healthcare Network Revenue ₹ cr ↑ 54% YOY Gross Margin ₹ cr ↑ 324 bps YOY EBITDA ₹ cr ↑ 556 bps YOY 10 2.0% 80.0 12.0% 685.5 70.1 10.2% 5.8 70.0 5 0.8% 1.0% 591.3 10.0% 60.0 7.6% 0 0.0% 7.0% 8.0% 445.5 50.0 H1FY23 H2FY23 H1FY24 45.2 -5 -1.0% 40.0 6.0% 31.3 30.0 -10
Slide 9: Most Capital Efficient Player in Industry
Most Capital Efficient Player in Industry Working Capital (No of Days) Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Inventory 65 61 52 43 42 Working Capital Days ↓ 37% YOY 60 56 18% Receivable 11 13 10 12 10 54 16% 50 46 Payable 20 19 16 12 17 15% 44 14% 15% 40 36 12% 13% Working Capital (No of Days) 56 54 46
Slide 10: Pillars of Growth
Pillars of Growth Growing Platform in ePharmacy Consolidation in Indian Pharma Distribution Diagnostic Services To launch eHealth app “Genu Health” 9
Slide 11: Growing Platform in ePharmacy
Growing Platform in ePharmacy Strategic partnership built on strong capabilities 75.10% 24.90% stake stake • Large consumer base • Most efficient supply chain & fulfilment capabilities • Established consumer tech capabilities • Direct procurement relationship with 250+ Pharma Companies • Huge brand
Slide 12: Structural Shift – Consolidation on way in Indian Pharma Distribution
Structural Shift – Consolidation on way in Indian Pharma Distribution Pharmaceutical wholesaling/distribution is highly consolidated industry in most of the developed countries (period last 2 to 3 decades). India to witness similar consolidation in Pharmaceutical distribution with fewer having major
Slide 13: Pharma eDistribution – Digital Supply Chain of Pharmaceuticals & Other Healthcare Products
Pharma eDistribution – Digital Supply Chain of Pharmaceuticals & Other Healthcare Products • Digital Supply Chain poised to transform the Indian Pharma distribution benefiting everyone with Pharma Companies major beneficiary • Improved Business Forecasting Digital supply chain can lower • Inventory
Slide 14: Benefitting Pharma & FMCG Cos.
Benefitting Pharma & FMCG Cos. • End to End tracking of Inventory up to Retailers with real time data • Better managed inventory leading to reduced return of expired stocks • Better production and distribution planning • New drugs can be introduced faster • Huge scope for Pharma Companies for their
Slide 15: Benefitting Retailers - Transforming Economics & Lives of Retailers
Benefitting Retailers - Transforming Economics & Lives of Retailers Traditional Distributors Benefits to Retailers • Full visibility of Inventory online • Reduction of Inventory Lead Time • Sourcing from Multiple Distributors • 100% fulfilment • Lower Working Capital requirement • Fulfilment gaps •
Slide 16: Empowering Retailers – One Stop eProcurement Solution
Empowering Retailers – One Stop eProcurement Solution Widest Availability and 100% Genuine High Margins with Fulfilment of Products Products Transparent Pricing (65000+ Products) Automated Procurement Timely Delivery Clear Return Policy 15
Slide 17: Snapshot
Snapshot Genu Path Labs, an NABL ACCREDITED LAB, where everything revolves around Meticulous Assay of Quality Evidence. Highly experienced Clinical Team, Advanced High End Lab Equipment, Stringent Quality Norms – EQAS, ILC, Strong Process Control (QuaGenLR) – we employ all of these at Genu 35+ Sampl
Slide 18: GENU Health app - Under making of Powerful Health Solutions
GENU Health app - Under making of Powerful Health Solutions • Direct service to the consumers from Genu Path Labs as D2C Brand offering diagnostic services with seamless integration of technology • Centred around preventive care, diagnostic services, management of surgery and hospital care, health/d
Slide 19: Sastasundar Group – Value Proposition
Sastasundar Group – Value Proposition • Best in class Customer Experience driven by Value Pricing, Quality and Tech • Clear visibility of high growth with EBITDA + model • Capital efficient with high ROCE • Strong MOAT ⁻ Established Business Technology with highly efficient supply chain ⁻ Managing 1
Slide 20: Experienced Board of Directors
Experienced Board of Directors FCA, FCS and FCM by education and has an experience of FCA by education and is a seasoned entrepreneur with more than 23 years working as an entrepreneur and a experience in scaling businesses from scratch. social worker. Areas of work include digital platform of
Slide 21: Experienced Management Team – Healthcare Network
Experienced Management Team – Healthcare Network Sachin Mittal COO Vinay Khaitan CTO Dinkar Bagaria CFO Past Experience - Amazon, Novartis Past Experience - Flipkart Group, Past Experience – TIL Ltd, SPML Infra, SastaSundar Group, GEO India McNally Bharat, Balasore Alloys 10+ Years of Experience 25+
Slide 22: Q2 FY24 Consolidated Profit & Loss Statement
Q2 FY24 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q2 FY24 Q2 FY23 Y-o-Y Q1 FY24 Q-o-Q H1 FY24 H1 FY23 Y-o-Y Revenue from Operations 355.4 253.9 40.0% 330.1 7.7% 685.5 445.6 53.8% Cost of Materials Consumed 320.3 235.0 295.1 615.4 414.4 Gross Profit 35.1 18.9 85.7% 35.0 0.3% 70.1 31.
Slide 23: Balance Sheet As on 30th Sep 2023
Balance Sheet As on 30th Sep 2023 Equity & Liabilities (Rs. Crs) Sep-23 Mar-23 Assets (Rs. Crs) Sep-23 Mar-23 Property, Plant and Equipment 67.2 68.1 Equity Share Capital 31.8 31.8 Capital Work-in-Progress 0.5 1.0 Other Equity# 949.2 961.7 Intangibles Assets 0.1 0.1 Total Equity 981.0 993.5 Goodwill
Slide 24: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crs) Sep-23 Sep-22 Cash Flow from Operating Activities Profit before Tax 29.7 (23.0) Adjustment for Non-Operating Items (20.4) 3.4 Operating Profit before Working Capital Changes 9.3 (19.6) Changes in Working Capital 17.1 56.1 Cash Generated from Ope
Slide 25: Breakup of Revenue
Breakup of Revenue Particulars (Rs. Crs) Q2 FY24 Q2 FY23 Q1 FY24 FY23 Health Buddy supply chain 251.6 210.6 254.3 848.0 Retailer Shakti 102.9 42.4 75.1 185.6 Genu Path Labs 0.9 0.9 0.7 3.3 Healthcare Network 355.4 253.9 330.1 1,036.9 Financial Services 12.8 6.2 18.1 26.5 Total Revenue 368.2 260.1 34
Slide 26: Breakup of PBT
Breakup of PBT Particulars (Rs. Crs) Q2 FY24 Q2 FY23 Q1 FY24 FY23 Health Buddy supply chain 4.3 (9.8) 6.0 (37.6) Retailer Shakti (2.8) (7.5) (2.1) (12.9) Genu Path Labs (2.1) (1.7) (1.8) (7.6) Healthcare Network (0.6) (19.0) 2.1 (58.1) Financial Services 11.3 8.5 17.0 20.7 Total 10.7 (10.5) 19.1 (37
Slide 27: Annual Financial Highlights
Annual Financial Highlights Rs. In Crs Revenue from Operations Gross Profit Q4 4.5% 8.8% 6.5% 7.4% Q3 169% +353% Q2 1,037 77 Q1 312 24 622 48 540 280 11 41 158 22 132 10 385 12 141 8 116 134 254 17 19 155 13 10 103 140 5 92 4 134 169 191 5 12 13 12 74 3 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Gross
Slide 28: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Revenue from Operations 1,036.9 623.0 540.0 384.0 215.6 Cost of Materials Consumed 960.4 582.5 492.5 366.9 199.5 Gross Profit 76.5 40.5 47.5 17.1 16.1 GP % 7.4% 6.5% 8.8% 4.5% 7.5% Employee Benef
Slide 29: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Assets (Rs. Crs) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 68.1 57.2 57.3 60.2 62.7 Capital Work-in-Progress 1.0 0.4 0.1 0.0 0.
Slide 30: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Cash Flow from Operating Activities Profit before Tax (122.3) 1,109.5 (16.4) (57.6) (41.8) Adjustment for Non-Operating Items 84.0 (1,151.0) (3.2) 4.8 7.8 Operating Profit before Working Capital Chan
Slide 31: 'Being Genuine' is Our Core Value 'Being Child' is Our Culture
‘Being Genuine’ is Our Core Value ‘Being Child’ is Our Culture 30
Slide 32: Thank You
Company: Thank You SastaSundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh – Company Secretary Email Id : investors@sastasundar.com www.sastasundarventures.com Investor Relations Partner: Orient Capital (a division of Link Group) Ronak Jain Irfan Raeen Ronak.jain@linkintime.co.in Ir
Sastasundar Ventures — Investor Presentation (November 2023) on 6ix